litlas
Log inCreate account

Nancy L. Bartlett

Active 1994–2025

205
Papers
42,015
Citations
96
h-index
194
i10-index

Citations

Citations per year for Nancy L. Bartlett1989: 3 citations1992: 1 citations1994: 2 citations1995: 8 citations1996: 9 citations1997: 11 citations1998: 5 citations1999: 4 citations2000: 8 citations2001: 11 citations2002: 31 citations2003: 45 citations2004: 38 citations2005: 68 citations2006: 42 citations2007: 52 citations2008: 29 citations2009: 28 citations2010: 31 citations2011: 75 citations2012: 138 citations2013: 120 citations2014: 152 citations2015: 195 citations2016: 160 citations2017: 279 citations2018: 344 citations2019: 1,548 citations2020: 2,088 citations2021: 2,065 citations2022: 1,780 citations2023: 1,397 citations2024: 2,335 citations2025: 1,199 citations2026: 15 citations1990–1991: no citations, so these years are not shown1993: no citations, so this year is not shown

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 4,806 citing papers, 29% of this breakdownChina: 1,583 citing papers, 9.6% of this breakdownGermany: 1,103 citing papers, 6.7% of this breakdownUnited Kingdom: 920 citing papers, 5.6% of this breakdownItaly: 903 citing papers, 5.4% of this breakdownFrance: 849 citing papers, 5.1% of this breakdownCanada: 604 citing papers, 3.6% of this breakdownSpain: 596 citing papers, 3.6% of this breakdownSwitzerland: 493 citing papers, 3% of this breakdownAustralia: 439 citing papers, 2.6% of this breakdownNetherlands: 437 citing papers, 2.6% of this breakdownJapan: 350 citing papers, 2.1% of this breakdown
0%29%Other 21.1%

Institutions

Fields

  • Medicine81.5%
  • Immunology and Microbiology9.4%
  • Biochemistry, Genetics and Molecular Biology7.1%
  • Engineering0.4%
  • Materials Science0.4%
  • Economics, Econometrics and Finance0.2%
  • Other1%

Topics

  • CAR-T cell therapy research15.6%
  • Lymphoma Diagnosis and Treatment12.4%
  • Chronic Lymphocytic Leukemia Research4.9%
  • Immune Cell Function and Interaction4.6%
  • Virus-based gene therapy research3.1%
  • Cancer Immunotherapy and Biomarkers2.8%
  • Other56.6%

Coauthors

All papers

Open in search
  1. Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma

    Authors: Sattva S. Neelapu, Frederick L. Locke, Nancy L. Bartlett, Lazaros J. Lekakis, David B. Miklos, Caron A. Jacobson, Ira Braunschweig, Olalekan O. Oluwole, Tanya Siddiqi, Yi Lin, John M. Timmerman, Patrick J. Stiff, Jonathan W. Friedberg, Ian W. Flinn, André Goy, Brian T. Hill, Mitchell R. Smith, Abhinav Deol, Umar Farooq, Peter A. McSweeney, Javier Muñoz, Irit Avivi, Januario E. Castro, Jason R. Westin, Julio C. Chávez, Armin Ghobadi, Krishna V. Komanduri, Ronald Levy, Eric D. Jacobsen, Thomas E. Witzig, Patrick M. Reagan, Adrian Bot, John M. Rossi, Lynn Navale, Yizhou Jiang, Jeff Aycock, Meg Elias, David Chang, Jeff Wiezorek, William Y. Go - New England Journal of Medicine 2017 cited by 5,915

  2. Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1–2 trial

    Authors: Frederick L. Locke, Armin Ghobadi, Caron A. Jacobson, David B. Miklos, Lazaros J. Lekakis, Olalekan O. Oluwole, Yi Lin, Ira Braunschweig, Brian T. Hill, John M. Timmerman, Abhinav Deol, Patrick M. Reagan, Patrick J. Stiff, Ian W. Flinn, Umar Farooq, André Goy, Peter A. McSweeney, Javier Muñoz, Tanya Siddiqi, Julio C. Chávez, Alex F. Herrera, Nancy L. Bartlett, Jeffrey S. Wiezorek, Lynn Navale, Allen Xue, Yizhou Jiang, Adrian Bot, John M. Rossi, Jaeyeon Kim, William Y. Go, Sattva S. Neelapu - The Lancet Oncology 2018 cited by 2,251

  3. Genetics and Pathogenesis of Diffuse Large B-Cell Lymphoma

    Authors: Roland Schmitz, George W. Wright, Da Wei Huang, Calvin A. Johnson, James D. Phelan, James Q. Wang, Sandrine Roulland, Monica Kasbekar, Ryan M. Young, Arthur L. Shaffer, Daniel J. Hodson, Wenming Xiao, Xin Yu, Yandan Yang, Hong Zhao, Weihong Xu, Xuelu Liu, Bin Zhou, Wei Du, Wing C. Chan, Elaine S. Jaffe, Randy D. Gascoyne, Joseph M. Connors, Elı́as Campo, Armando López‐Guillermo, Andreas Rosenwald, German Ott, Jan Delabie, Lisa M. Rimsza, Kevin Tay Kuang Wei, Andrew D. Zelenetz, John P. Leonard, Nancy L. Bartlett, Bao Tran, Jyoti Shetty, Yongmei Zhao, Dan Soppet, Stefania Pittaluga, Wyndham H. Wilson, Louis M. Staudt - New England Journal of Medicine 2018 cited by 2,261

  4. CD47 Blockade by Hu5F9-G4 and Rituximab in Non-Hodgkin’s Lymphoma

    Authors: Ranjana H. Advani, Ian W. Flinn, Leslie Popplewell, Andres Forero, Nancy L. Bartlett, Nilanjan Ghosh, Justin Kline, Mark Roschewski, Ann S. LaCasce, Graham P. Collins, Thu Ha Tran, Judith Lynn, James Y. Chen, Jens-Peter Volkmer, Balaji Agoram, Jie Huang, Ravindra Majeti, Irving L. Weissman, Chris H. Takimoto, Mark P. Chao, Sonali M. Smith - New England Journal of Medicine 2018 cited by 1,120

  5. Safety and efficacy of mosunetuzumab, a bispecific antibody, in patients with relapsed or refractory follicular lymphoma: a single-arm, multicentre, phase 2 study

    Authors: Lihua E. Budde, Laurie H. Sehn, Matthew J. Matasar, Stephen J. Schuster, Sarit Assouline, Pratyush Giri, John Kuruvilla, Miguel Canales, Sascha Dietrich, Keith Fay, Matthew Ku, Loretta J. Nastoupil, Chan Y. Cheah, Michael C. Wei, Shen Yin, Chi‐Chung Li, Huang Huang, Antonia Kwan, Elicia Penuel, Nancy L. Bartlett - The Lancet Oncology 2022 cited by 436

  6. 5-Year Follow-Up Supports Curative Potential of Axicabtagene Ciloleucel in Refractory Large B-Cell Lymphoma (ZUMA-1)

    Authors: Sattva S. Neelapu, Caron A. Jacobson, Armin Ghobadi, David B. Miklos, Lazaros J. Lekakis, Olalekan O. Oluwole, Yi Lin, Ira Braunschweig, Brian T. Hill, John M. Timmerman, Abhinav Deol, Patrick M. Reagan, Patrick J. Stiff, Ian W. Flinn, Umar Farooq, André Goy, Peter A. McSweeney, Javier Muñoz, Tanya Siddiqi, Julio C. Chávez, Alex F. Herrera, Nancy L. Bartlett, Adrian A. Bot, Rhine R. Shen, Jinghui Dong, Kanwarjit Singh, Harry Miao, Jaeyeon Kim, Yan Zheng, Frederick L. Locke - Blood 2023 cited by 228

  7. Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia

    Authors: Jan A. Burger, Alessandra Tedeschi, Paul M. Barr, Tadeusz Robak, Carolyn Owen, Paolo Ghia, Osnat Bairey, Peter Hillmen, Nancy L. Bartlett, Jianyong Li, David Simpson, Sebastian Grosicki, Stephen Devereux, Helen O. McCarthy, Steven Coutré, Hang Quach, Gianluca Gaïdano, Zvenyslava Maslyak, Don A. Stevens, Ann Janssens, Fritz Offner, Jiřı́ Mayer, Michael O’Dwyer, Andrzej Hellmann, Anna Schuh, Tanya Siddiqi, Aaron Polliack, Constantine S. Tam, Deepali Suri, Mei Cheng, Fong Clow, Lori Styles, Danelle F. James, Thomas J. Kipps - New England Journal of Medicine 2015 cited by 1,562

  8. Single-Agent Mosunetuzumab Shows Durable Complete Responses in Patients With Relapsed or Refractory B-Cell Lymphomas: Phase I Dose-Escalation Study

    Authors: Lihua E. Budde, Sarit Assouline, Laurie H. Sehn, Stephen J. Schuster, Sung-Soo Yoon, Dok Hyun Yoon, Matthew J. Matasar, Francesc Bosch, Won Seog Kim, Loretta J. Nastoupil, Ian W. Flinn, Mazyar Shadman, Catherine Diefenbach, Carol O'Hear, Huang Huang, Antonia Kwan, Chi-Chung Li, Emily C. Piccione, Michael C. Wei, Shen Yin, Nancy L. Bartlett - Journal of Clinical Oncology 2021 cited by 290

  9. Ibrutinib Regimens versus Chemoimmunotherapy in Older Patients with Untreated CLL

    Authors: Jennifer A. Woyach, Amy S. Ruppert, Nyla A. Heerema, Weiqiang Zhao, Allison M. Booth, Wei Ding, Nancy L. Bartlett, Danielle M. Brander, Paul M. Barr, Kerry A. Rogers, Sameer A. Parikh, Steven Coutré, Arti Hurria, Jennifer R. Brown, Gerard Lozanski, James S. Blachly, Hatice Gülçin Özer, Brittny Major‐Elechi, Briant Fruth, Sreenivasa Nattam, Richard A. Larson, Harry P. Erba, Mark R. Litzow, Carolyn Owen, Charles Kuzma, Jeremy S. Abramson, Richard F. Little, Scott E. Smith, Richard M. Stone, Sumithra J. Mandrekar, John C. Byrd - New England Journal of Medicine 2018 cited by 952

  10. Overall Survival with Brentuximab Vedotin in Stage III or IV Hodgkin’s Lymphoma

    Authors: Stephen M. Ansell, John Radford, Joseph M. Connors, Monika Długosz‐Danecka, Won-Seog Kim, Andrea Gallamini, Radhakrishnan Ramchandren, Jonathan W. Friedberg, Ranjana H. Advani, Martin Hutchings, Andrew M. Evens, Piotr Smolewski, Kerry J. Savage, Nancy L. Bartlett, Hyeon‐Seok Eom, Jeremy S. Abramson, Cassie Dong, Frank Campana, Keenan Fenton, Markus Puhlmann, David J. Straus - New England Journal of Medicine 2022 cited by 328

  11. Consensus recommendations on the management of toxicity associated with CD3×CD20 bispecific antibody therapy

    Authors: Jennifer L. Crombie, Tara Graff, Lorenzo Falchi, Yasmin Karimi, Rajat Bannerji, Loretta J. Nastoupil, Catherine Thiéblemont, Rénata Ursu, Nancy L. Bartlett, Victoria Nachar, J. Weiss, Jane Osterson, Krish Patel, Joshua Brody, Jeremy S. Abramson, Matthew A. Lunning, Nirav N. Shah, Ayed O. Ayed, Manali Kamdar, Benjamin M. Parsons, Paolo F. Caimi, Ian W. Flinn, Alex F. Herrera, Jeffrey P. Sharman, Marshall McKenna, Philippe Armand, Brad S. Kahl, Sonali M. Smith, Andrew D. Zelenetz, Lihua E. Budde, Martin Hutchings, Tycel Phillips, Michael Dickinson - Blood 2024 cited by 131

  12. The ECHELON-2 Trial: 5-year results of a randomized, phase III study of brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma

    Authors: Steven M. Horwitz, Owen A. O’Connor, Barbara Pro, Lorenz Trümper, Swaminathan P. Iyer, Ranjana H. Advani, Nancy L. Bartlett, Jacob Haaber Christensen, F. Morschhauser, Eva Domingo‐Doménech, Giuseppe Rossi, Woo Seob Kim, Tatyana Feldman, Tobias Menne, David Belada, Árpád Illés, Kensei Tobinai, Kunihiro Tsukasaki, S.-P. Yeh, Andrei R. Shustov, Andreas Hüttmann, Kerry J. Savage, Sam Yuen, Pier Luigi Zinzani, Harry Miao, Veronica Bunn, Keenan Fenton, Michelle A. Fanale, Markus Puhlmann, Tim Illidge - Annals of Oncology 2021 cited by 262

  13. Brentuximab Vedotin with Chemotherapy for Stage III or IV Hodgkin’s Lymphoma

    Authors: Joseph M. Connors, Wojciech Jurczak, David J. Straus, Stephen M. Ansell, Won S. Kim, Andrea Gallamini, Anas Younes, Sergey Alekseev, Árpád Illés, Marco Picardi, Ewa Lech‐Marańda, Yasuhiro Oki, Tatyana Feldman, Piotr Smolewski, Kerry J. Savage, Nancy L. Bartlett, Jan Walewski, Robert Chen, Radhakrishnan Ramchandren, Pier Luigi Zinzani, David Cunningham, András Rosta, Neil C. Josephson, Eric Song, Jessica Sachs, Rachael Liu, Hina Jolin, Dirk Huebner, John Radford - New England Journal of Medicine 2017 cited by 764

  14. CAR-modified memory-like NK cells exhibit potent responses to NK-resistant lymphomas

    Authors: Margery Gang, Nancy D. Marín, Pamela Wong, Carly C. Neal, Lynne Marsala, Mark P. Foster, Timothy Schappe, Wei Meng, Jennifer Tran, Maximilian O. Schaettler, Marco L. Davila, Feng Gao, Amanda F. Cashen, Nancy L. Bartlett, Neha Mehta–Shah, Brad S. Kahl, Miriam Kim, Matthew Cooper, John F. DiPersio, Melissa M. Berrien-Elliott, Todd A. Fehniger - Blood 2020 cited by 224

  15. Prophylactic corticosteroid use in patients receiving axicabtagene ciloleucel for large B‐cell lymphoma

    Authors: Olalekan O. Oluwole, Krimo Bouabdallah, Javier Muñoz, Sophie de Guibert, Julie M. Vose, Nancy L. Bartlett, Yi Lin, Abhinav Deol, Peter A. McSweeney, André Goy, Marie José Kersten, Caron A. Jacobson, Umar Farooq, Monique C. Minnema, Catherine Thiéblemont, John M. Timmerman, Patrick J. Stiff, Irit Avivi, Dimitrios Tzachanis, Jaeyeon Kim, Zahid Bashir, Jeff McLeroy, Yan Zheng, John M. Rossi, Lisa D. Johnson, Lovely Goyal, Tom van Meerten - British Journal of Haematology 2021 cited by 214

  16. Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial

    Authors: Steven M. Horwitz, Owen A. O’Connor, Barbara Pro, Tim Illidge, Michelle A. Fanale, Ranjana H. Advani, Nancy L. Bartlett, Jacob Haaber Christensen, Franck Morschhauser, Eva Domingo‐Doménech, Giuseppe Rossi, Won Seog Kim, Tatyana Feldman, Anne Lennard, David Belada, Árpád Illés, Kensei Tobinai, Kunihiro Tsukasaki, Su‐Peng Yeh, Andrei R. Shustov, Andreas Hüttmann, Kerry J. Savage, Sam Yuen, Swaminathan P. Iyer, Pier Luigi Zinzani, Zhaowei Hua, Meredith Little, Shangbang Rao, Joseph Woolery, Thomas Manley, Lorenz Trümper, David M. Aboulafia, Ranjana H. Advani, Önder Alpdoğan, Kiyoshi Ando, Luca Arcaini, Luca Baldini, Naresh Bellam, Nancy L. Bartlett, David Belada, Dina Ben Yehuda, Fabio Benedetti, Peter Borchman, Dominique Bordessoule, Pauline Brice, Javier Briones, Dolores Caballero, Angelo Michele Carella, Hung Chang, June Weon Cheong, Seok‐Goo Cho, Ilseung Choi, Sylvain Choquet, Andrei Coliţă, Angela Giovanna Congui, Francesco d’Amore, Nam H. Dang, Kelly Davison, Sophie de Guibert, Peter de Nully Brown, Vincent Delwail, Judit Demeter, Francesco Di Raimondo, Young Rok, Eva Domingo, Michael G. Douvas, Martin Dreyling, Thomas Ernst, Michelle A. Fanale, Keith Fay, Tatyana Feldman, Silvia Ferrero, Ian W. Flinn, Andres Forero‐Torres, Christopher P. Fox, Jonathan W. Friedberg, Noriko Fukuhara, José A. García‐Marco, Jorge Gayoso Cruz, José Codina, Rémy Gressin, Andrew Grigg, Ronit Gurion, Jacob Haaber Christensen, Corinne Haïoun, Roman Hájek, Mathias Hänel, Kiyohiko Hatake, Robert Hensen, Netanel A. Horowitz, Steven M. Horwitz, Andreas Hüttmann, Árpád Illés, Tim Illidge, Kenichi Ishizawa, Miguel Islas‐Ohlmayer, Eric D. Jacobsen, Murali Janakiram, Wojciech Jurczak, Mark Kaminski and 69 more - The Lancet 2018 cited by 726

  17. Phase 1 Results of ZUMA-1: A Multicenter Study of KTE-C19 Anti-CD19 CAR T Cell Therapy in Refractory Aggressive Lymphoma

    Authors: Frederick L. Locke, Sattva S. Neelapu, Nancy L. Bartlett, Tanya Siddiqi, Julio C. Chávez, Chitra Hosing, Armin Ghobadi, Lihua E. Budde, Adrian Bot, John M. Rossi, Yizhou Jiang, Allen Xue, Meg Elias, Jeff Aycock, Jeff Wiezorek, William Y. Go - Molecular Therapy 2017 cited by 619

  18. Dose-Adjusted EPOCH-R Compared With R-CHOP as Frontline Therapy for Diffuse Large B-Cell Lymphoma: Clinical Outcomes of the Phase III Intergroup Trial Alliance/CALGB 50303

    Authors: Nancy L. Bartlett, Wyndham H. Wilson, Sin‐Ho Jung, Eric D. Hsi, Matthew J. Maurer, Levi Pederson, Mei‐Yin C. Polley, Brandelyn N. Pitcher, Bruce D. Cheson, Brad S. Kahl, Jonathan W. Friedberg, Louis M. Staudt, Nina D. Wagner‐Johnston, Kristie A. Blum, Jeremy S. Abramson, Nishitha Reddy, Jane N. Winter, Julie Chang, Ajay K. Gopal, Amy Chadburn, Susan Mathew, Richard I. Fisher, Kristy L. Richards, Heiko Schöder, Andrew D. Zelenetz, John P. Leonard - Journal of Clinical Oncology 2019 cited by 423

  19. Results of a Pivotal Phase II Study of Brentuximab Vedotin for Patients With Relapsed or Refractory Hodgkin's Lymphoma

    Authors: Anas Younes, Ajay K. Gopal, Scott E. Smith, Stephen M. Ansell, Joseph D. Rosenblatt, Kerry J. Savage, Radhakrishnan Ramchandren, Nancy L. Bartlett, Bruce D. Cheson, Sven de Vos, Andres Forero‐Torres, Craig H. Moskowitz, Joseph M. Connors, Andreas Engert, Emily K. Larsen, Dana A. Kennedy, Eric L. Sievers, Robert Chen - Journal of Clinical Oncology 2012 cited by 1,520

  20. Mosunetuzumab monotherapy is active and tolerable in patients with relapsed/refractory diffuse large B-cell lymphoma

    Authors: Nancy L. Bartlett, Sarit Assouline, Pratyush Giri, Stephen J. Schuster, Chan Y. Cheah, Matthew J. Matasar, Gareth P. Gregory, Dok Hyun Yoon, Mazyar Shadman, Keith Fay, Sung‐Soo Yoon, Carlos Panizo, Ian W. Flinn, Anna Johnston, Francesc Bosch, Laurie H. Sehn, Michael C. Wei, Shen Yin, Iris To, Chi‐Chung Li, Huang Huang, Antonia Kwan, Elicia Penuel, Lihua E. Budde - Blood Advances 2023 cited by 93

  21. Brentuximab Vedotin (SGN-35) for Relapsed CD30-Positive Lymphomas

    Authors: Anas Younes, Nancy L. Bartlett, John P. Leonard, Dana A. Kennedy, Carmel M. Lynch, Eric L. Sievers, Andres Forero‐Torres - New England Journal of Medicine 2010 cited by 1,353

  22. SWOG S1826, a randomized study of nivolumab(N)-AVD versus brentuximab vedotin(BV)-AVD in advanced stage (AS) classic Hodgkin lymphoma (HL).

    Authors: Alex F. Herrera, Michael LeBlanc, Sharon M. Castellino, Hongli Li, Sarah C. Rutherford, Andrew M. Evens, Kelly Davison, Angela Punnett, David Hodgson, Susan K. Parsons, Sairah Ahmed, Carla Casulo, Nancy L. Bartlett, Joo Y. Song, Richard F. Little, Brad S. Kahl, John P. Leonard, Kara M. Kelly, Sonali M. Smith, Jonathan W. Friedberg - Journal of Clinical Oncology 2023 cited by 117

  23. Brentuximab vedotin in combination with nivolumab in relapsed or refractory Hodgkin lymphoma: 3-year study results

    Authors: Ranjana H. Advani, Alison J. Moskowitz, Nancy L. Bartlett, Julie M. Vose, Radhakrishnan Ramchandren, Tatyana Feldman, Ann S. LaCasce, Beth Christian, Stephen M. Ansell, Craig H. Moskowitz, Lisa Brown, Chiyu Zhang, David R. Taft, Sahar Ansari, Mariana Sacchi, Linda Ho, Alex F. Herrera - Blood 2021 cited by 218

  24. A phase 1b study of AFM13 in combination with pembrolizumab in patients with relapsed or refractory Hodgkin lymphoma

    Authors: Nancy L. Bartlett, Alex F. Herrera, Eva Domingo‐Doménech, Amitkumar Mehta, Andres Forero‐Torres, Ramón García‐Sánz, Philippe Armand, Sumana Devata, Antonia Rodríguez Izquierdo, Izidore S. Lossos, Craig B. Reeder, Taimur Sher, Robert Chen, Sylvia E. Schwarz, Leila Alland, András Strassz, Kim Prier, Cassandra Choe-Juliak, Stephen M. Ansell - Blood 2020 cited by 151